{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:26Z","timestamp":1772165666295,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Major Infectious Prevention and Treatment Program in the 13th Five-Year Plan","award":["2018zx10302104-001"],"award-info":[{"award-number":["2018zx10302104-001"]}]},{"name":"Special Foundation for Innovation Development in Hunan Province","award":["2020SK21362"],"award-info":[{"award-number":["2020SK21362"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Though bictegravir\/emtricitabine\/tenofovir (BIC\/FTC\/TAF) have been regulatory approved and included in the National Reimbursement Drug List in China, due to the affordability concern, generic version of efavirenz\u2009+\u2009lamivudine\u2009+\u2009tenofovir (EFV\u2009+\u20093TC\u2009+\u2009TDF) is still recommended as the first-line therapy in the clinical guideline and widely used in clinical practice. The aim of the study is to assess the persistence with first-line BIC\/TAF\/TAF and EFV\u2009+\u20093TC\u2009+\u2009TDF in newly treated HIV-1 patients in the real-world setting in Hunan Province in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of the medical records of HIV patients initiating first-line antiretroviral therapy in the First Hospital of Changsha in January 1st, 2021-July 31st, 2022 was conducted. Persistence was assessed as the number of days on the therapy from the index until treatment discontinuation or end of data availability. Kaplan-Meier Curves and Cox Proportional Hazard models were used to evaluate the discontinuation rates. Subgroup analysis was performed excluding BIC\/FTC\/TAF patients with treatment discontinuation due to economic reason, and EFV\u2009+\u20093TC\u2009+\u2009TDF patients with a viral load\u2009&gt;\u2009500,000 copies\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 310 eligible patients were included in the study, with 244 and 66 patients in the BIC\/FTC\/TAF group and EFV\u2009+\u20093TC\u2009+\u2009TDF group, respectively. Compared with EFV\u2009+\u20093TC\u2009+\u2009TDF patients, BIC\/FTC\/TAF patients were older, more living in the capital city currently, and had significantly higher total cholesterol and low-density level (all p\u2009&lt;\u20090.05). No significant difference was shown in the time to discontinuation between BIC\/FTC\/TAF patients and EFV\u2009+\u20093TC\u2009+\u2009TDF patients. After excluding BIC\/FTC\/TAF patients with treatment discontinuation due to economic reason, EFV\u2009+\u20093TC\u2009+\u2009TDF group were shown to have a significantly higher risk of discontinuation than BIC\/FTC\/TAF group (hazard ratio [HR]\u2009=\u200911.1, 95% confidence interval [CI]\u2009=\u20091.3\u201393.2). After further removing the EFV\u2009+\u20093TC\u2009+\u2009TDF patients with a viral load\u2009&gt;\u2009500,000 copies\/mL, the analysis showed similar results (HR\u2009=\u200910.1, 95% CI\u2009=\u20091.2\u201384.1). 79.4% of the EFV\u2009+\u20093TC\u2009+\u2009TDF patients discontinued treatment due to clinical reasons, while 83.3% of the BIC\/FTC\/TAF patients discontinued treatment due to economic reasons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with BIC\/FTC\/TAF, EFV\u2009+\u2009TDF\u2009+\u20093TC patients were significantly more likely to discontinue the first-line treatment in Hunan Province in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08359-w","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T07:02:24Z","timestamp":1686553344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment persistence of bictegravir\/emtricitabine\/tenofovir alafenamide and efavirenz\u2009+\u2009lamivudine\u2009+\u2009tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China"],"prefix":"10.1186","volume":"23","author":[{"given":"Cao","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Gang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xingzhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Guoqiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"issue":"48","key":"8359_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.46234\/ccdcw2021.249","volume":"3","author":"N He","year":"2021","unstructured":"He N. Research Progress in the epidemiology of HIV\/AIDS in China. China CDC Wkly. 2021;3(48):1022\u201330.","journal-title":"China CDC Wkly"},{"issue":"23","key":"8359_CR2","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1097\/CM9.0000000000001842","volume":"134","author":"JJ Xu","year":"2021","unstructured":"Xu JJ, et al. Prevention and control of HIV\/AIDS in China: lessons from the past three decades. Chin Med J (Engl). 2021;134(23):2799\u2013809.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"8359_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.46234\/ccdcw2020.020","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Disproportionate increase of new diagnosis of HIV\/AIDS infection by sex and age - China, 2007\u20132018. China CDC Wkly. 2020;2(5):69\u201374.","journal-title":"China CDC Wkly"},{"key":"8359_CR4","unstructured":"[Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)] Zhonghua nei ke za zhi, 2021. 60(12): p. 1106\u201328."},{"key":"8359_CR5","unstructured":"The National Healthcare Security Administration. A renewed catalog of drugs covered by its national medical insurance systemhttp:\/\/www.gov.cn\/zhengce\/zhengceku\/2021-12\/03\/content_5655651.htm Accessed on Oct 1st, 2022, 2021."},{"issue":"11\u201312","key":"8359_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.cr.7290362","volume":"15","author":"FJ Zhang","year":"2005","unstructured":"Zhang FJ, et al. Current progress of China\u2019s free ART program. Cell Res. 2005;15(11\u201312):877\u201382.","journal-title":"Cell Res"},{"key":"8359_CR7","doi-asserted-by":"crossref","unstructured":"Guidelines for diagnosis and treatment of HIV\/AIDS in China (2005). Chin Med J (Engl), 2006. 119(19): p. 1589\u2013608.","DOI":"10.1097\/00029330-200610010-00002"},{"issue":"1","key":"8359_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11904-019-00478-x","volume":"17","author":"W Cao","year":"2020","unstructured":"Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV\/AIDS in China: successes over two decades and remaining Challenges. Curr HIV\/AIDS Rep. 2020;17(1):26\u201334.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"8359_CR9","unstructured":"AIDS Professional Group. Society of Infectious Diseases Chinese Medical Association: guidelines for diagnosis and treatment of HIV\/AIDS in China (2011). ZHONGHUA CHUAN RAN BING ZA ZHI. 2011;29(10):629\u201340."},{"issue":"4","key":"8359_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jac\/dkab481","volume":"77","author":"J Ambrosioni","year":"2022","unstructured":"Ambrosioni J, et al. Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77(4):1133\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"8359_CR11","doi-asserted-by":"publisher","first-page":"ofac018","DOI":"10.1093\/ofid\/ofac018","volume":"9","author":"K Mounzer","year":"2022","unstructured":"Mounzer K, et al. Advanced HIV infection in Treatment-Na\u00efve individuals: effectiveness and persistence of recommended 3-Drug regimens. Open Forum Infect Dis. 2022;9(3):ofac018.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"8359_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","volume":"17","author":"J Cohen","year":"2020","unstructured":"Cohen J, et al. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res Ther. 2020;17(1):12.","journal-title":"AIDS Res Ther"},{"issue":"11","key":"8359_CR13","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jiac.2022.07.005","volume":"28","author":"X Wang","year":"2022","unstructured":"Wang X, Schmerold L, Naito T. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan. J Infect Chemother. 2022;28(11):1464\u201370.","journal-title":"J Infect Chemother"},{"issue":"10","key":"8359_CR14","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/jac\/dkv183","volume":"70","author":"N Apostolova","year":"2015","unstructured":"Apostolova N, et al. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015;70(10):2693\u2013708.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"8359_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/09540121.2019.1622645","volume":"32","author":"P Qin","year":"2020","unstructured":"Qin P, et al. Efavirenz use and neurocognitive performance among older people living with HIV who were on antiretroviral therapy. AIDS Care. 2020;32(1):12\u201320.","journal-title":"AIDS Care"},{"issue":"23","key":"8359_CR16","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1097\/CM9.0000000000001824","volume":"134","author":"H Xia","year":"2021","unstructured":"Xia H, et al. Switching from efavirenz to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV. Chin Med J (Engl). 2021;134(23):2850\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"8359_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/aid.2019.0193","volume":"36","author":"JKC Law","year":"2020","unstructured":"Law JKC, Butler LT, Hamill MM. Predictors of discontinuation of Efavirenz as Treatment for HIV, due to Neuropsychiatric Side Effects, in a multi-ethnic sample in the United Kingdom. AIDS Res Hum Retroviruses. 2020;36(6):459\u201366.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"8359_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00365548.2013.773067","volume":"45","author":"PD Leutscher","year":"2013","unstructured":"Leutscher PD, et al. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis. 2013;45(8):645\u201351.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"8359_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/ejhpharm-2020-002374","volume":"29","author":"N Fern\u00e1ndez-Bargiela","year":"2022","unstructured":"Fern\u00e1ndez-Bargiela N, et al. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm. 2022;29(4):207\u201311.","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"8359_CR20","doi-asserted-by":"publisher","first-page":"e0153489","DOI":"10.1371\/journal.pone.0153489","volume":"11","author":"L Niu","year":"2016","unstructured":"Niu L, et al. The Mental Health of People living with HIV in China, 1998\u20132014: a systematic review. PLoS ONE. 2016;11(4):e0153489.","journal-title":"PLoS ONE"},{"key":"8359_CR21","doi-asserted-by":"crossref","unstructured":"\u201cIf you get AIDS\u2026 you have to endure it alone\u201d: understanding the social constructions of HIV\/AIDS in China Soc Sci Med, 2007. 65(2): p.\u00a0284 \u2013 95.","DOI":"10.1016\/j.socscimed.2007.03.031"},{"key":"8359_CR22","doi-asserted-by":"publisher","first-page":"579448","DOI":"10.3389\/fpsyt.2021.579448","volume":"12","author":"W Hua","year":"2021","unstructured":"Hua W, et al. Neuropsychiatric adverse events during 12 months of treatment with Efavirenz in Treatment-Na\u00efve HIV-Infected patients in China: a prospective cohort study. Front Psychiatry. 2021;12:579448.","journal-title":"Front Psychiatry"},{"issue":"4","key":"8359_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/infdis\/jiaa125","volume":"222","author":"B Surial","year":"2020","unstructured":"Surial B, et al. Changes in renal function after switching from TDF to TAF in HIV-Infected individuals: a prospective cohort study. J Infect Dis. 2020;222(4):637\u201345.","journal-title":"J Infect Dis"},{"issue":"1","key":"8359_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12981-021-00420-5","volume":"18","author":"K Abe","year":"2021","unstructured":"Abe K, et al. Renal function in japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study. AIDS Res Ther. 2021;18(1):94.","journal-title":"AIDS Res Ther"},{"issue":"3","key":"8359_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jiac.2021.11.016","volume":"28","author":"S Hikasa","year":"2022","unstructured":"Hikasa S, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: a retrospective observational study. J Infect Chemother. 2022;28(3):396\u2013400.","journal-title":"J Infect Chemother"},{"issue":"3","key":"8359_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3947\/ic.2020.52.3.381","volume":"52","author":"JW Seo","year":"2020","unstructured":"Seo JW, et al. Recovery of Tenofovir-induced nephrotoxicity following switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive patients. Infect Chemother. 2020;52(3):381\u20138.","journal-title":"Infect Chemother"},{"key":"8359_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijid.2019.07.011","volume":"87","author":"X Tao","year":"2019","unstructured":"Tao X, et al. Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2019;87:43\u201353.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"8359_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12879-022-07576-z","volume":"22","author":"C Zhou","year":"2022","unstructured":"Zhou C, et al. Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China. BMC Infect Dis. 2022;22(1):602.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"8359_CR29","doi-asserted-by":"publisher","first-page":"e0181997","DOI":"10.1371\/journal.pone.0181997","volume":"12","author":"B Lin","year":"2017","unstructured":"Lin B, et al. HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China. PLoS ONE. 2017;12(7):e0181997.","journal-title":"PLoS ONE"},{"issue":"9","key":"8359_CR30","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00705-021-05140-9","volume":"166","author":"H Yuan","year":"2021","unstructured":"Yuan H, et al. Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000\u20132016. Arch Virol. 2021;166(9):2451\u201360.","journal-title":"Arch Virol"},{"issue":"2","key":"8359_CR31","doi-asserted-by":"publisher","first-page":"e0165110","DOI":"10.1371\/journal.pone.0165110","volume":"12","author":"F Zhang","year":"2017","unstructured":"Zhang F, et al. An analysis of drug resistance among people living with HIV\/AIDS in Shanghai, China. PLoS ONE. 2017;12(2):e0165110.","journal-title":"PLoS ONE"},{"issue":"6","key":"8359_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1089\/aid.2021.0079","volume":"38","author":"Q Wei","year":"2022","unstructured":"Wei Q, et al. High rate of HIV-1 Drug Resistance in antiretroviral therapy-failure patients in Liaoning Province, China. AIDS Res Hum Retroviruses. 2022;38(6):502\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"8359_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12879-020-05124-1","volume":"20","author":"D Yuan","year":"2020","unstructured":"Yuan D, et al. Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study. BMC Infect Dis. 2020;20(1):443.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"8359_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12985-021-01653-6","volume":"18","author":"Y Lan","year":"2021","unstructured":"Lan Y, et al. Transmitted drug resistance and transmission clusters among HIV-1 treatment-na\u00efve patients in Guangdong, China: a cross-sectional study. Virol J. 2021;18(1):181.","journal-title":"Virol J"},{"key":"8359_CR35","doi-asserted-by":"crossref","unstructured":"Cao X, et al. Prevalence of primary drug resistance among newly diagnosed HIV-1 infected individuals in Hunan province, China. AIDS Res Hum Retroviruses; 2023.","DOI":"10.1089\/aid.2022.0077"},{"issue":"1","key":"8359_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12913-020-05687-4","volume":"20","author":"X Zhuang","year":"2020","unstructured":"Zhuang X, et al. Analysis of hospitalization expenses of 610 HIV\/AIDS patients in Nantong, China. BMC Health Serv Res. 2020;20(1):813.","journal-title":"BMC Health Serv Res"},{"key":"8359_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1741-7015-9-6","volume":"9","author":"F Zhou","year":"2011","unstructured":"Zhou F, et al. Expenditures for the care of HIV-infected patients in rural areas in China\u2019s antiretroviral therapy programs. BMC Med. 2011;9:6.","journal-title":"BMC Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08359-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T07:04:05Z","timestamp":1686553445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8359"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08359-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2351107\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. The ethics committee of the First Hospital of Changsha approved the study protocol. The data used in this study was anonymized before its use. The need for informed consent was waived by the ethics committee\/Institutional Review Board of the First Hospital of Changsha because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual person\u2019s data was shown separately. All data are presented as a whole.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"396"}}